Status:
COMPLETED
Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
Lead Sponsor:
Institut Bergonié
Conditions:
Intraductal Carcinoma and Lobular Carcinoma in Situ
Eligibility:
FEMALE
18+ years
Brief Summary
When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND). Th...
Eligibility Criteria
Inclusion
- Older than 18 years.
- Preoperative histological diagnosis obtained by biopsy
- Ductal carcinoma in situ (DCIS) or pure micro-invasive (DCIS-MI)
- Indication of mastectomy
- Patient signed informed consent
Exclusion
- Age \< 18 years
- Infiltrating ductal carcinoma (TCC) diagnosed on biopsy
- Pure DCIS diagnosed by lumpectomy
- DCIS can take a conservative treatment
- Mastectomy chosen by the patient
- History of breast carcinoma in situ or invasive ipsilateral
- Prior radiotherapy to the ipsilateral breast
- History of axillary lateral homo
- Patient who for reasons psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study
- Patient deprived of liberty or under guardianship
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT01841749
Start Date
January 1 2008
End Date
December 1 2010
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, Aquitaine, France, 33000